Algorae Signs Distribution Agreement with Dr. Reddy's
Filed with ASX · · 2 pages · English
AI-enabled pharmaceutical company Algorae Pharmaceuticals Ltd (ASX: 1AI) is pleased to announce it has entered into a distribution agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY, NYSE: RDY) to supply the chemotherapy medicine Capecitabine (Capecitabine 500mg Tab) into the Australian market. As per the agreement terms, the first shipment is expected to arrive
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Loyalty Options Offer
- Prospectus - Loyalty Options Offer
- AlgoraeOS Version 2 AI Platform Launched
- Algorae Signs Binding Term Sheet with Cadila Pharmaceuticals
- Algorae Signs Exclusive License Agreement with Sakar
Later from Algorae Pharmaceuticals
- Peter Mac Testing Validates AlgoraeOS - v2 Launched
- Algorae Receives $384,466.78 R&D Tax Incentive Refund
- AlgoraeOS v2 Identifies 90 Drug Combination Candidates
- $3 million Debt Facility Secured with ScotPac
- Quarterly Activities Report /Appendix 4C Cash Flow Statement
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals